Evidence map›Paper›PMID 40654336›Full record

ReviewActa pharmaceutica Sinica. B2025

Nanomedicine-driven tumor glucose metabolic reprogramming for enhanced cancer immunotherapy.

Chenwei Jiang, Minglu Tang, Yun Su, Junjie Xie, Qi Shang, Mingmei Guo, Xiaoran An, Longfei Lin, Ruibin Wang, Qian Huang and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Chenwei JiangSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
Minglu TangSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
Yun SuDepartment of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.
Junjie XieSchool of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
Qi ShangSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
Mingmei GuoSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
Xiaoran AnSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
Longfei LinInstitute of Chinese Materia Medical, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Ruibin WangInstrumental Analysis Center, Shanghai Jiao Tong University, Shanghai 200240, China.
Qian HuangMonyan Pharmaceutical (Shanghai) Co., Ltd., Shanghai 201400, China.
Guangji ZhangSchool of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Hui LiInstitute of Chinese Materia Medical, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Feihu WangSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumors exhibit abnormal glucose metabolism, consuming excessive glucose and excreting lactate, which constructs a tumor microenvironment that facilitates cancer progression and disrupts immunotherapeutic efficacy. Currently, tumor glucose metabolic dysregulation to reshape the immunosuppressive microenvironment and enhance immunotherapy efficacy is emerging as an innovative therapeutic strategy. However, glucose metabolism modulators lack specificity and still face significant challenges in overcoming tumor delivery barriers, microenvironmental complexity, and metabolic heterogeneity, resulting in poor clinical benefit. Nanomedicines, with their ability to selectively target tumors or immune cells, respond to the tumor microenvironment, co-deliver multiple drugs, and facilitate combinatorial therapies, hold significant promise for enhancing immunotherapy through tumor glucose metabolic reprogramming. This review explores the complex interactions between tumor glucose metabolism-specifically metabolite transport, glycolysis processes, and lactate-and the immune microenvironment. We summarize how nanomedicine-mediated reprogramming of tumor glucose metabolism can enhance immunotherapy efficacy and outline the prospects and challenges in this field.

Indexed as

Cancer immunotherapyGlucose metabolismGlycolysisLactateNanomedicine

Identifiers

PMID40654336
PMCPMC12254754

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.